Viewing Study NCT02484404


Ignite Creation Date: 2025-12-24 @ 7:59 PM
Ignite Modification Date: 2026-01-10 @ 3:40 PM
Study NCT ID: NCT02484404
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-11-25
First Post: 2015-06-25
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Sponsor: National Cancer Institute (NCI)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module